Emmaus Life Sciences (OTCMKTS:EMMA) Releases Earnings Results

Emmaus Life Sciences (OTCMKTS:EMMA) posted its quarterly earnings data on Friday. The company reported $0.02 earnings per share for the quarter, Zacks reports.

Emmaus Life Sciences Stock Performance

Shares of OTCMKTS EMMA remained flat at $0.01 during midday trading on Friday. The stock had a trading volume of 70,008 shares, compared to its average volume of 69,714. The stock has a fifty day simple moving average of $0.01 and a 200-day simple moving average of $0.01. The stock has a market cap of $807,185.00, a price-to-earnings ratio of -0.09 and a beta of 9.37. Emmaus Life Sciences has a one year low of $0.01 and a one year high of $0.02.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc is a publicly traded specialty pharmaceutical company focused on the development and commercialization of therapies for sickle cell disease and other serious hematological disorders. Its lead product, Endari® (L-glutamine oral powder), received U.S. Food and Drug Administration approval in 2017 for reducing the acute complications of sickle cell disease in patients aged five years and older. Through targeted research and development, Emmaus is also advancing additional pipeline candidates aimed at addressing oxidative stress and protein aggregation pathways that underlie various blood disorders.

Emmaus markets Endari in the United States and has entered into licensing agreements to distribute the therapy in regions including sub-Saharan Africa, the Middle East, North Africa and Latin America.